Simplify Logo

Full-Time

Scientist I

Proteomics

Posted on 7/9/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$115k - $138kAnnually

+ Equity Awards

Mid, Senior

San Carlos, CA, USA

Hybrid position requiring onsite presence in Redwood City, California.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD or equivalent industry experience in chemical biology, analytical chemistry or related discipline
  • Hands-on experience preparing, analyzing and interpreting proteomics datasets generated from biological samples
  • Deep knowledge of proteomics principles and sample preparation workflows
  • Ability to independently analyze proteomics data
  • Strong problem-solving skills with sound technically driven decision-making ability
  • Effective written and verbal communication skills as well as interpersonal skills
  • A creative team-player with capacity to be effective in a dynamic company environment
Responsibilities
  • Design and execute proteomics experiments to answer a variety of biological and mechanistic questions
  • Lead projects to innovate and improve sample preparation workflows, with an eye towards scalability and automation
  • Assist in maintenance of group instrumentation, including LC-MS/MS system
  • Collaborate cross-functionally with biology, biochemistry, chemistry and structural biology colleagues
  • Generate data in a timely manner and maintain detailed experimental records
  • Regularly and effectively communicate findings at project team and company meetings

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

18%

1 year growth

44%

2 year growth

131%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE